• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AJMC® in the Press, December 6, 2019

Article

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

An article appearing in Purdue University’s Research Foundation News, titled “An engineering approach to reduce the pain of chemotherapy,” referenced a May 2019 In Focus Blog article published on the website of The American Journal of Managed Care® (AJMC®), titled “Chemotherapy Demand Will Rise Significantly by 2040, and Workforce Will Need to Expand With It.”

Valdosta Daily Times’ article, “Nearly a Quarter of a Million Prescribers Using Surescripts Prescription Price Transparency Tool to View Patient Medication Cost Information,” cited a study published in the January 2006 issue of AJMC®, titled “Varying Pharmacy Benefits With Clinical Status: The Case of Cholesterol-lowering Therapy.” The study stressed the importance of cholesterol-lowering therapy in reducing hospitalizations and emergency department use.

AJMC®’s sister site, The Center for Biosimilars®, was featured in the December 2, 2019, daily regulatory news and intelligence briefing from Regulatory Focus. The article, “Mylan and Biocon Launch Biosimilar Trastuzumab, Ogivri, in the United States,” was included in the section In Focus: US.

A piece by McKnight’s Long-Term Care News referenced a study published in the January 2019 issue of AJMC®: “Mind the Gap: The Potential of Alternative Health Information Exchange.” The study found that open forms of health information exchange selection tools remain critical for comprehensive coverage of patient transitions.

Related Videos
Pat Van Burkleo
Video 1 - "Diagnosing and Understanding the Pathogenesis of Bronchiectasis"
Video 4 - "Challenges in Autoantibody Screening for Type 1 Diabetes"
Jeff Stark, MD, vice president, head of medical immunology, UCB
Video 7 - "Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients"
Video 7 - "Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients"
Video 6 - "Community Partnership: Increasing Public Awareness of CVD"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.